Your time is valuable, so we've drilled down the three most important medtech stories from the past week. But feel free to click the headline to read beyond the blurb.Image by OpenClipart-Vectors on Pixabay
Bigfoot Biomedical is on track to submit its diabetes technology for FDA clearance this year, and the product could hit the market by year end. It helps that the company has some friends with deep pockets like Abbott and other investors that kicked in a total of $45 million in an initial tranche of a series C financing. Bigfoot's injection-based digitized insulin dosing platform uses a connected insulin pen-based system that integrates Abbott’s FreeStyle Libre glucose sensing technology.
DexCom plans to double capacity for its G6 continued glucose management (CGM) system by the end of 2020 while also moving forward with development of its less expensive and much thinner G7 CGM. During DexCom's presentation at the recent J.P. Morgan Healthcare Conference, CEO Kevin Sayer told attendees this will be a big year for G7. “We’ll finish those final product design tweaks, scale-up manufacturing, get a clinical trial started and executed for the year, and [anticipate] a late 2020 launch with a full launch in 2021.”
Medtronic's initiative, Igniting Women to Lead, has been recognized through a 2020 Catalyst Award. The honor recognizes corporations that have made it a priority to foster an inclusive workplace where women can advance. Today, 40% of Medtronic therapy revenue is led by women.